Fund managers including Saville Capital, Wilson Asset Management, Investors Mutual Limited, SG Hiscock & Company and Selector Funds Management have invested in Imricor Medical Systems, Inc (ASX:IMR).

Managers highlight regulatory progress, including multiple FDA 510(k) clearances and premarket approval submissions for its ablation catheter and generator, as well as first US commercial sales to Rady Children's Hospital. SG Hiscock sees MRI-guided ablation as a potential shift away from fluoroscopy, with the $60 million raise funding commercialisation.

Saville Capital notes recent capital raisings contributed to register churn and short-term share price weakness, and Imricor's growth depends on full FDA premarket approval for its ablation products and hospital adoption, which carry regulatory and commercial timing risk.

Imricor Medical Systems, Inc., founded in 2006 and headquartered in Burnsville, MN, designs, manufactures, and distributes MRI-compatible medical devices for cardiac catheter ablation. Its product portfolio includes the Advantage-MR EP Recorder/Stimulator, the Vision-MR Ablation Catheter for type I atrial flutter treatment, and the Vision-MR Dispersive Electrode, which reduces eddy currents during MR scanning. Additionally, the company conducts contract research and licenses its proprietary intellectual property for use in implantable devices.